Neuromorphic Computing Pioneer GrAI Matter Labs Raises $15M to Bring AI to Every Device on the Edge
GrAI Matter Labs, a pioneer of ultra-low power neuromorphic computing, today announced it has closed its Series A financing round of $15 million. Inspired by the biology of the human brain, GrAI Matter Labs’ technology will be implemented as programmable application processors which can bring AI with machine learning capabilities to every device on the edge. The consortium of investors is led by iBionext and also includes 360 Capital Partners and 3T Finance.
A New Paradigm in Computing
GrAI Matter Lab’s technology is based on breakthrough research carried out at the Vision Institute (UPMC) in Paris on the human brain during the past 20 years. Inspired by the human biology, the company’s unique neuromorphic computing paradigm overcomes the limitations of Von Neumann machines, offering massively parallel and fully programmable sensor analytics and machine learning at significantly reduced power consumption.
“Our neuromorphic approach to computing and machine learning achieved impressive results in a hardware/software prototyping project under a DARPA grant. The prototype demonstrated how a new compute paradigm could enable AI completely locally on an edge device without cloud computing support,” said Ryad Benosman, co-Founder and Chief Scientific Officer of GrAI Matter Labs.
AI to Every Device on the Edge
GrAI Matter Lab’s programmable application processors will provide AI with machine learning capabilities across the Internet of Things. These processors will power autonomous navigation platforms, enabling cars, robots and drones to navigate our world with performance/power optimized AI for safety and convenience. Other focus areas include intelligent cognitive assistants to bring AI to smart homes and smart phones, and wearable AI for smart health monitoring, practically invisible and consuming minimal power.
“GrAI Matter Labs is pushing the boundaries for silicon compute and machine learning architectures based on learnings from biology and the human brain. We are thrilled with the future prospects of GrAI Matter Labs and look forward to grow the company to become a disruptive force in how AI can be leveraged in ways never thought possible,” said Bernard Gilly, Chairman of iBionext.
“By being able to bring AI to every device on the edge with our low-power neuromorphic compute platform, we can enable entirely new use models and applications for smart computing. This Series A round of financing will help us to ramp our engineering teams in Eindhoven and Paris, and to move rapidly from technology development to market deployment,” said Ingolf Held, CEO of GrAI Matter Labs.
About GrAI Matter Labs
GrAI Matter Labs (aka GML) was founded in 2016 as Brainiac within the iBionext Start-up Studio in Paris by Ryad Benosman, Bernard Gilly, Giacomo Indiveri, Xavier Lagorce, Sio-Hoi Leng, Bernabe Linares-Barranco and Atul Sinha, a team combining extensive experience in neuromorphic computing, silicon design, and entrepreneurship.
GML has offices in Paris, Eindhoven, The Netherlands and Silicon Valley. The company is driven by a team of visionary and seasoned engineers, and is backed by leading investors including iBionext, 360 Capital Partners and 3T Finance. More information can be found at www.graimatterlabs.ai.
Created in September 2015, iBionext is a management company and a start-up studio dedicated to the development of innovative start-ups in healthcare. This initiative, launched by Bernard Gilly in 2012, aims to transform technological breakthrough ideas into leading innovative start-ups in the fields of HealthTech and related industrial applications. All these companies are grouped on a single site named the "Passage de l’Innovation" in Paris, France.
Since 2012, 8 companies where created within the iBionext ecosystem - Pixium Vision (Euronext: PIX), GenSight Biologics (Euronext: SIGHT), Gecko Biomedical, Prophesee (previously Chronocam), ChronoLife, BrainEver, Tilak Healthcare and GrAI Matter Labs (previously Brainiac). iBionext and its companies have raised over 360 million euros in capital (of which € 90 million raised by iBionext Growth Fund). 7 clinical trials are currently underway worldwide and 190 experienced professionals have joined these companies.
iBionext Growth Fund was created in 2016 to finance the growth of new companies selected within the iBionext network.
To find out more: http://ibionext.com/
About 360 Capital Partners
360 Capital Partners is an early stage Venture Capital firm investing in disruptive deep-tech & digital innovations across Europe. The firm has a 20-year track record in supporting talented technology entrepreneurs achieve their ambition of creating game-changing enterprises. 360 Capital is led by a diverse, and experienced group of professionals across Paris & Milan with over €300M of assets under management and an active portfolio of over 50 companies.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer19.3.2019 20:00:00 CET | Pressemelding
SOTIO, a biotechnology company owned by the PPF Group, presented results from SOV02, its Phase II clinical trial evaluating DCVAC/OvCa, an active cellular immunotherapy product, in patients with recurrent ovarian cancer at 2019 SGO’s 50 th Annual Meeting on Women's Cancer today. Final analysis of SOV02 shows that DCVAC/OvCa decreased the risk of death significantly compared to patients who did not receive DCVAC/OvCa. Clinical trial results were presented during today’s SGO 2019 Plenary Session by SOV02 principal investigator David Cibula, MD, PhD from General University Hospital in Prague (Czech Republic). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005837/en/ In the randomized, open label SOV02 clinical trial, patients with recurrent ovarian cancer received DCVAC/OvCa in combination with platinum-based chemotherapy. Compared to patients who did not receive DCVAC, it decreased the risk of death by 62%. The combinati
OCP Announces Date of Fourth Quarter and Full Year 2018 Earnings19.3.2019 19:00:00 CET | Pressemelding
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2018 results on Monday, March 25, 2019. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 9:00 a.m. EDT, 2:00 p.m. Morocco time (GMT+1), and 1:00 p.m. London time (GMT). OCP senior management will host a conference call to discuss fourth quarter and full year 2018 results at 10:00 a.m. EDT, 3:00 p.m. Morocco time (GMT+1), and 2:00 p.m. London time (GMT) on Monday, March 25, 2019 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing email@example.com About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s
HCL and Xerox Expand Strategic Partnership to Accelerate Operational Transformation19.3.2019 16:51:00 CET | Pressemelding
HCL Technologies (HCL), a leading global technology company, announced that it signed a managed services agreement with Xerox (NYSE: XRX). Under the terms of the agreement, HCL will manage portions of Xerox’s shared services, including global administrative and support functions, including, among others, selected information technology and finance functions (excluding accounting). Leveraging HCL’s global scale and capabilities, Xerox will strategically evolve its shared services into process-first, technology-led digital operations. This seven-year agreement for an incremental $1.3 billion continues to build on the success of the Xerox-HCL relationship, which began in 2009 with product engineering and support services. Under that agreement, HCL currently manages aspects of Xerox’s mechanical, electrical and software engineering activities for printer and imaging product lines. Together, HCL and Xerox have delivered 215 U.S. patents and have created world-class R&D labs that are tightly
Abzena and Lipum AB Sign Integrated CMC Agreement to Produce a Novel Biologic for Autoimmune Inflammatory Diseases19.3.2019 15:18:00 CET | Pressemelding
Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory diseases, including juvenile idiopathic arthritis. The 18-month program includes: development of a research cell bank using Abzena’s proprietary cell line and ambr® 15 automated high throughput bioreactors, generation of master cell banks, scale up using an ambr® 250 during process development, followed by cGMP manufacturing in Sartorius 500 L single use stirred tank bioreactors for clinical material. The work will take place at Abzena’s sites in Cambridge, UK and San Diego, USA. Jonathan Goldman, CEO of Abzena, said: “Autoimmune inflammatory diseases such as juvenile idiopathic arthritis represent significant unmet medical need. We are
Saudi Arabia Takes Another Step Forward in Its Transformation Drive19.3.2019 14:00:00 CET | Pressemelding
King Salman bin Abdulaziz of Saudi Arabia today launched four wellbeing projects for the kingdom’s capital Riyadh, which will significantly improve the lives of its citizens, transform the city into an attractive destination and make it one of the world’s most livable cities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005574/en/ The four wellbeing projects - King Salman Park, Sports Boulevard, Green Riyadh and Riyadh Art – complement the Saudi Vision 2030’s “Quality of Life” Program and are aligned with the U.N. Sustainable Development Goals, to create sustainable cities and communities, while driving urgent action against climate change. Developed with a government investment of US$23 billion, the four projects will offer opportunities worth US$15 billion for the private sector to invest in the residential, commercial, recreational and wellness areas. In addition to providing tens of thousands of new jobs, they wi